Cofetuzumab pelidotin
Product Sizes
5 mg
HY-P99829-5MG
10 mg
HY-P99829-10MG
1 mg
HY-P99829-1MG
About this Product
- SKU:
- HY-P99829
- Additional Names:
- PF-06647020; ABBV-647; h6M24-vc0101
- Application:
- Antibody Microarray
- CAS Number:
- 1869937-48-3
- Extra Details:
- Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024; IgG1) joined to an auristatin microtubule inhibitor payload; auristatin-0101 (Aur0101; HY-12522); by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research[1][2][3].
- Molecular Weight:
- 151784 (average)
- Purity:
- 99.67
- References:
- [1]Marc Damelin, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017 Jan 11;9(372):eaag2611. |[2]Chao Kong, et al. MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. Mol Cancer Ther. 2023 Oct 2;22(10):1128-1143. |[3]Masaru Katoh. Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis. nn Transl Med. 2017 Dec;5(23):462.
- Research Area:
- Cancer
- Shipping Conditions:
- Dry Ice
- Storage Conditions:
- -80[o]C; protect from light
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Conjugated Protein
- Pathway:
- Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton
